Immunology and Microbiology
Graft-Versus-Host Disease
100%
Bone Marrow Transplantation
71%
Cyclophosphamide
50%
Acute Graft Versus Host Disease
49%
T Cell
45%
Transplant Procedure
40%
Allogeneic Bone Marrow Transplantation
38%
Hematopoietic Cell
35%
Cell Transplantation
35%
Tumor Necrosis Factor
33%
Conditioning
27%
Mouse
25%
Hematopoietic Stem Cell Transplantation
22%
Allogeneic Hematopoietic Stem Cell Transplantation
19%
Allogeneic Stem Cell Transplantation
18%
Tumor Necrosis Factor Receptor
16%
Chronic Graft Versus Host Disease
14%
Etanercept
13%
Engraftment
13%
Overall Survival
10%
Blood Plasma
10%
Stem Cell Transplantation
10%
Mouse Model
10%
Target Organ
9%
Cytokine
8%
Mesenchymal Stem Cell
8%
Immunosuppression
7%
Syngenic
7%
Wild Type
7%
Inflammatory Cytokine
7%
Drug Megadose
7%
Bronchoalveolar Lavage Fluid
6%
Host
6%
Aplastic Anemia
6%
Neutralization
6%
Tumor Necrosis Factor Receptor 1
6%
Stem Cell
5%
Tacrolimus
5%
Myeloid
5%
Granulocyte Colony-Stimulating Factor
5%
Allotransplantation
5%
Immunosuppressive Therapy
5%
Leukocyte Recruitment
5%
Perforin
5%
Keyphrases
Graft-versus-host Disease (GvHD)
89%
Post-transplantation Cyclophosphamide (PTCy)
34%
Bone Marrow Transplantation
33%
Allogeneic Bone Marrow Transplantation
27%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
26%
Hematopoietic Stem Cell Transplantation
21%
Hematopoietic Cell Transplantation
17%
Idiopathic Pneumonia Syndrome
17%
Haploidentical Transplantation
16%
Lung Injury
15%
Pediatric
14%
Graft-versus-leukemia Effect
12%
Donor T Cell
12%
Tumor Necrosis Factor-α
12%
Lung
12%
Transplantation
11%
Non-relapse Mortality
10%
Mouse Model
10%
High Risk
10%
Hematological Malignancies
9%
Myeloablative
9%
Non-infectious
9%
Cryo-imaging
9%
T Cells
8%
Confidence Interval
8%
TNF Receptor 1 (TNFR1)
8%
Marrow Transplantation
8%
Nonmyeloablative
8%
Nonmalignant
8%
Total Body Irradiation
7%
Graft-versus-host Disease Prophylaxis
7%
Etanercept
7%
HLA-haploidentical
7%
Overall Survival
7%
Haploidentical
7%
Stem Cell Transplantation
6%
Severe Aplastic Anemia
6%
Young Adult Patients
6%
Bronchiolitis Obliterans Syndrome
6%
Pediatric Hematopoietic Stem Cell Transplantation
6%
Pulmonary Complications
6%
Target Organ
6%
Lipopolysaccharide
6%
Allogeneic
6%
Cyclophosphamide
6%
Pretransplant
6%
Clinical Trials
6%
HLA Matching
6%
Transplant Complications
5%
Immunosuppressive Therapy
5%
Medicine and Dentistry
Graft Versus Host Reaction
44%
Bone Marrow Transplantation
32%
Hematopoietic Stem Cell
31%
Cell Transplantation
30%
Pediatrics
29%
Transplantation
29%
Idiopathic Pneumonia Syndrome
26%
Hematopoietic Stem Cell Transplantation
26%
Cyclophosphamide
23%
Disease
17%
T Cell
17%
Acute Graft Versus Host Disease
15%
Tumor Necrosis Factor
14%
Allogenic Bone Marrow Transplantation
14%
Hematologic Malignancy
12%
Allogeneic Stem Cell Transplantation
11%
Allogeneic Hematopoietic Stem Cell Transplantation
11%
Clinical Trial
10%
Tumor Necrosis Factor Receptor
9%
Graft Versus Leukemia Effect
9%
Bronchiolitis Obliterans
9%
Biological Marker
8%
Chronic Graft Versus Host Disease
8%
Whole Body Radiation
8%
Stem Cell Therapy
8%
Engraftment
7%
Pediatrics Patient
7%
Diagnosis
7%
Hazard Ratio
6%
Leukemia
6%
Injury
6%
Etanercept
6%
Graft Failure
5%
Lipopolysaccharide
5%
Prophylaxis
5%
Overall Survival
5%
Conditioning
5%
Immunosuppressive Treatment
5%
Liver Venoocclusive Disease
5%
Malignant Neoplasm
5%
Acute Myeloid Leukemia
5%
Acute Lung Injury
5%
Cumulative Incidence
5%